Finasteride is a 5α-reductase inhibitor, commonly used in the treatment of symptomatic benign prostatic hyperplasia, if the patient is intolerant of this product or unsuitable for use, the patient can switch to dutasteride, eplerenone, etc. under the guidance of a physician for treatment. Dutasteride is an androgenic drug that can also be used to treat moderate and severe symptoms of BPH. It may also be used in patients with moderate to severe symptoms of BPH to reduce the risk of acute urinary retention and surgery. For patients who are unfit to take Finasteride, this product may be taken instead of therapy under the supervision of a physician. Eprileptal is a selective and non-competitive steroid type II 5a-reductase inhibitor for the treatment of benign prostatic hyperplasia. The mechanism of action of Eprileptal is to inhibit the conversion of testosterone to dihydrotestosterone and reduce the level of dihydrotestosterone in the prostate gland, leading to atrophy of the hyperplastic prostate gland. It should be noted that the above medications should be contraindicated in those who are allergic to dutasteride, eplerenone, other 5α-reductase inhibitors, or any excipients, and in those with severe hepatic impairment. The above drugs are prescription drugs, and their specific use should also be carried out under the supervision of a physician on medical advice.